Ebselen

Research use only, not for human use.

Ebselen is a mimic of glutathione peroxidase and can also react with peroxynitrite.

Ebselen is a mimic of glutathione peroxidase and can also react with peroxynitrite. It is being investigated as a possible treatment for reperfusion injury and stroke, hearing loss and tinnitus, and bipolar disorder.(In Vitro):Ebselen (SPI-1005; 0.4-100 μM; 20-24 hours) shows strong antiviral effects at a concentration of 10 μM treatment in COVID-19 virus infected Vero cells. Ebsele covalently binds to C145 of the catalytic dyad in COVID-19 virus Mpro.Ebselen inhibits early viral postentry events of the HIV-1 life cycle by impairing the incoming capsid uncoating process.Ebselen permeates the blood-brain barrier and inhibits endogenous inositol monophosphatase in mouse brain. Ebselen inhibits inositol monophosphatase (IMPase).Ebselen inhibits QSOX1 enzymatic activity and suppresses invasion of pancreatic, renal cancer cell lines.(In Vivo):Ebselen (5, 10 mg/kg; IP) decreases 5-HT2 agonist-induced head twitches in a dose-dependent manner.

Ebselen (SPI-1005; 0.4-100 μM; 20-24 hours) shows strong antiviral effects at a concentration of 10 μM treatment in COVID-19 virus infected Vero cells. Ebsele covalently binds to C145 of the catalytic dyad in COVID-19 virus Mpro.Ebselen inhibits early viral postentry events of the HIV-1 life cycle by impairing the incoming capsid uncoating process. Ebselen permeates the blood-brain barrier and inhibits endogenous inositol monophosphatase in mouse brain. Ebselen inhibits inositol monophosphatase (IMPase). Ebselen inhibits QSOX1 enzymatic activity and suppresses invasion of pancreatic, renal cancer cell lines. RT-PCR Cell Line:COVID-19 virus infected Vero cells Concentration: 0.4, 1.2, 3.7, 11.1, 33.3, 100 μM Incubation Time:20-24 hours Result:Showed strong antiviral effects at a concentration of 10 μM treatment.

Ebselen (5, 10 mg/kg; IP) decreases 5-HT2 agonist-induced head twitches in a dose-dependent manner. Animal Model:20-25 g 10-12 week old male C57Bl6 mice Dosage:5, 10 mg/kg Administration:IP Result:Decreased 5-HT2 agonist-induced head twitches in a dose-dependent manner.

SPI-1005 | SPI1005 | SPI 1005 | Ebselen | PZ 51 | PZ51 | PZ-51 | DR3305 | DR 3305 | DR-3305

Chromatin/Epigenetic

COX

COX

Inflammation/Immunology

——

60940-34-3

274.18

C13H9NOSe

>98% (HPLC)

Water: 10 mM

O=C1N(C2=CC=CC=C2)[Se]C3=CC=CC=C13

2-phenylbenzo[d][1,2]selenazol-3(2H)-one

(-20℃)

With Ice Pack

≥ 2 years